P
Prabhakar Reddy
Researcher at Emory University
Publications - 4
Citations - 292
Prabhakar Reddy is an academic researcher from Emory University. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 3, co-authored 4 publications receiving 151 citations.
Papers
More filters
Journal ArticleDOI
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots,Jeong-Joong Yoon,Robert M. Cox,Michael G Hart,Zachary M. Sticher,Negar Makhsous,Roland Plesker,Alec H. Barrena,Prabhakar Reddy,Deborah G. Mitchell,Ryan C. Shean,Gregory R. Bluemling,Alexander A. Kolykhalov,Alexander L. Greninger,Michael G. Natchus,George R. Painter,Richard K. Plemper +16 more
TL;DR: EIDD-2801 is created, an isopropylester prodrug of the ribonucleoside analog N4-hydroxycytidine that has shown broad anti-influenza virus activity in cultured cells and mice and is recommended as a clinical candidate with high potential for monotherapy of seasonal and pandemic influenza virus infections.
Journal ArticleDOI
Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts
Shijun Zhu,Terry W. Moore,Xiaoqian Lin,Nao Morii,Alessandra Mancini,Randy B. Howard,Deborah G. Culver,Richard F. Arrendale,Prabhakar Reddy,Taylor J. Evers,Hongzheng Zhang,Gabriel Sica,Zhuo Georgia Chen,Aiming Sun,Haian Fu,Fadlo R. Khuri,Dong M. Shin,James P. Snyder,Mamoru Shoji +18 more
TL;DR: The novel synthetic curcumin analog EF31 is efficacious in inhibiting the growth of Tu212 xenograft tumors and may be useful for treating head and neck squamous cell carcinoma.
Journal ArticleDOI
ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.
Katherine E. Squires,Douglas L. Mayers,Gregory R. Bluemling,Alexander A. Kolykhalov,David B. Guthrie,Prabhakar Reddy,Debbie G. Mitchell,Manohar Saindane,Zachary M. Sticher,Vindhya Edpuganti,Abel De La Rosa +10 more
TL;DR: ATI-2173 may provide an improved pharmacokinetic profile for clinical use, reducing systemic exposure of clevudine and potentially eliminating skeletal myopathy, by selectively delivering the 5′-monophosphate to the liver, while retaining the unique anti-HBV activity of the5′-triphosphate.
Journal ArticleDOI
Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Shijun Zhu,Terry W. Moore,Nao Morii,Randy B. Howard,Deborah G. Culver,Richard F. Arrendale,Prabhakar Reddy,Taylor J. Evers,Hongzheng Zhang,Gabriel Sica,Zhuo Georgia Chen,Aiming Sun,Haian Fu,Fadlo R. Khuri,Dong M. Shin,James P. Snyder,Mamoru Shoji +16 more
TL;DR: It is demonstrated that UBS109 is efficacious in retarding the growth of Tu212 (head and neck) squamous cell carcinoma (SCC) xenograft tumors in mice and may be useful for treating head and neck SCC tumors.